Jakob

Karma: 598

Research manager at ICFG.eu, board member at Langsikt.no, doing policy research to mitigate risks from biotechnology and AI. Ex-SecureBio manager, ex-McKinsey Global Institute fellow and founder of the McKinsey Effective Altruism community. Follow me on Twitter at @jgraabak

No, the EMH does not imply that markets have long AGI timelines

JakobApr 24, 2023, 8:27 AM

83 points

21 comments8 min readEA link

Visualizations of the significance—persistence—contingency framework

JakobSep 2, 2022, 6:22 PM

27 points

0 comments7 min readEA link

Is GiveWell underestimating the health value of lead eradication?

JakobAug 21, 2022, 3:13 PM

33 points

7 comments4 min readEA link

The 3rd wave of EA is coming—what does it mean for you?

JakobAug 19, 2022, 1:47 PM

44 points

4 comments5 min readEA link

Exit opportunities after management consulting

Vaidehi Agarwalla 🔸Aug 16, 2021, 10:54 AM

33 points

6 comments6 min readEA link

Why scale is overrated: The case for increasing EA policy efforts in smaller countries

Philip Hall AndersenAug 15, 2021, 5:48 PM

84 points

11 comments30 min readEA link

Maximizing impact during consulting: building career capital, direct work and more.

Vaidehi Agarwalla 🔸Aug 13, 2021, 1:59 PM

21 points

2 comments25 min readEA link

Considerations and advice on entering management consulting

Vaidehi Agarwalla 🔸Aug 11, 2021, 1:06 PM

51 points

9 comments15 min readEA link

Objectives of longtermist policy making

Henrik Øberg MyhreFeb 10, 2021, 6:26 PM

54 points

7 comments22 min readEA link